Wednesday, July 8, 2026

pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT

Cogent Biosciences

Cogent Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker COGT. Primary therapeutic focus areas include Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocy

275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US HQ
2014 Founded
283 Employees
Public company Type
COGT · NYSE Ticker
Company details
Status
Public
HQ
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
Founded
2014
Employees
283
Programs
13
Drugs
8
Patents
10
Clinical program

Bezuclastinib Tablets (Formulation A)

Phase 2 · small molecule · SSM

Bezuclastinib Tablets (Formulation A) for SSM is a Phase 2 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).

← All Cogent Biosciences projects Phase 2 small molecule active

Internal code CGT9486-21-202

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cogent Biosciences
Phase
Phase 2
Modality
small_molecule
Indication
SSM
Status
active
Trials
1